Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (17796)	5/2/2006 1:06:50 PM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[GNBT] I noticed ALY this AM when they reported Earnings. Nice Move. I'd Mention GNBT but if I do .. Ken will just want to short it again. Maybe I can Spook him enuff with this. >>Young Adult Type-1 Diabetes Mellitus<< stockcharts.com Message 22407038 Clinician Presents Generex Oral-lyn(TM) Clinical Data at the Pediatric Academic Societies' 2006 Annual Meeting Tuesday May 2, 8:00 am ET biz.yahoo.com TORONTO--(MARKET WIRE)--May 2, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that Dr. Jaime Guevara-Aguirre, M.D., of the Institute of Endocrinology IEMYR in Quito, Ecuador, was invited to make a late-breaker platform presentation of Generex Oral-lyn(TM) clinical data on May 1, 2006 at the Pediatric Academic Societies' 2006 Annual Meeting in San Francisco. ADVERTISEMENT Dr. Guevara's presentation was entitled "Preliminary Results from a 6-Month Study on the Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunch Time in Adolescent and Young Adult Type-1 Diabetes Mellitus Subjects Maintained on Basal Subcutaneous Glargine Insulin and Pre-Breakfast and Pre-Dinner Subcutaneous Regular Insulin." "We are most gratified that the scientific community has recognized the importance of this study and the significance of these preliminary results and invited the principal investigator to make a podium presentation of the clinical data at this important scientific symposium," said Anna Gluskin, President & Chief Executive Officer of Generex. Participating subjects in this 6-month study are 24 adolescents (12M; 12F) and five young adults (2M; 3F) referred to the Institute of Endocrinology IEMYR in various degrees of metabolic control as reflected by altered baseline measurements of glucose 236.6 (116.6) mg/dL; fructosamine 472.6 (126.6) umol/L; and glycosylated hemoglobin (HbA1c) 9.8 (2.3) g/dL. Baseline demographics of the 24 adolescents are: Age 14.7y (2.1); Bone age 14.1 (2.2); CA/BA 1.0 (0.1); Height 153.8cm (9.4); Weight 51.0kg (10.2); BMI 21.7 (3.2); Duration of DM 6.7 (2.8). Baseline demographics of the 5 young adults are: Age 20.6y (2.2); Bone age (BA) 18.8 (0.4); CA/BA 1.1 (0.1); Height 161.1cm (12.8); Weight 62.5kg (9.3); BMI 23.0 (1.8); Duration of DM 7.0 (1.7). Mean age for the entire group is 15.7y (3.0); BA 14.9 (2.7); CA/BA 1.1 (0.1); Duration of the DM is 6.8 (2.6). After stabilization with basal subcutaneous glargine insulin and three pre-prandial subcutaneous regular insulin injections, standard therapy continued for four weeks for comparison. Immediately thereafter, split doses of Generex Oral-lyn immediately before and after lunch replaced lunch time injections of regular insulin. Patient-collected glucose values, fructosamine, and HbA1c were compared weekly (3-4 weeks per each treatment). Values are reported at the end of each phase. • Generex Biotechnology Subsidiary Receives Patent From European Patent Office Market Wire (Mon 7:30am) • Generex Biotechnology Receives Additional Patent in Mexico Market Wire (Mon, Apr 24) • Generex Biotechnology Announces Results of a Trial Using Generex Oral-lyn(TM) in Adolescent and Young Adult Patients With Type-1 Diabetes Mellitus Market Wire (Mon, Apr 10) • Global Demand Supports Development of Avian Flu Treatments and Antiviral Drugs Market Wire (Mon, Apr 3)